Aditxt Opens its First High-Capacity Immune Monitoring Center in Richmond, VA

Rhea-AI Summary

Aditxt, Inc. (Nasdaq: ADTX) has launched its AditxtScore™ Center in Richmond, VA, a CLIA-validated facility capable of processing millions of immune system reports annually. This center is pivotal for commercializing the AditxtScore platform, which assesses individual immune biomarkers and aids in health monitoring. The recently commercialized AditxtScore for COVID-19 will detect antibodies against SARS-CoV-2. Aditxt focuses on technologies that enhance immune health, featuring both monitoring and reprogramming solutions.

Positive

• Opening of the AditxtScore Center enhances operational capabilities for immune system monitoring.
• The facility is designed to process millions of reports annually, indicating significant scalability.
• The AditxtScore platform is advancing towards commercialization, expanding the company's market potential.
• Recent commercial availability of AditxtScore for COVID-19 demonstrates immediate product relevance.

Negative

• None.

Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced the opening of its AditxtScore™ Center in Richmond, VA. This high-capacity, CLIA-validated immune monitoring center will be scalable to process several million complex immune system reports per year.

“The opening of the AditxtScore Center is a key step on AditxtScore’s path to market, serving as a critical enabler to commercializing a new platform for personalized health,” said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt. “In addition to its operational and commercial capabilities, this facility will also help accelerate new AditxtScore application development activities to address markets with significant growth potential.”

Introduced earlier this year in a joint press conference including Governor Ralph Northam and Richmond Mayor Levar Stoney, the AditxtScore Center was built to support the growth of the AditxtScore platform, a pioneering new approach to immune and health monitoring that provides a personalized profile of the immune system. By assessing an individual's immune biomarkers, AditxtScore is designed to measure indications of immune response to specific disease. AditxtScore applications include the recently commercialized AditxtScore for COVID-19, developed for use in detecting antibodies against SARS-CoV-2 antigens.

AditxtScore is offered through authorized channel partners. To find an AditxtScore Channel Partner near you, please visit www.aditxtscore.com. AditxtScore is available for use as a CLIA-validated laboratory developed test (LDT). This test is not for self-diagnosis and is not cleared nor approved by the FDA.

About Aditxt:

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. Aditxt’s immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005221/en/

FAQ

What is the AditxtScore Center and where is it located?

The AditxtScore Center is a CLIA-validated immune monitoring facility located in Richmond, VA, designed to process millions of immune reports annually.

What is the purpose of the AditxtScore platform?

The AditxtScore platform is aimed at monitoring immune health by assessing individual immune biomarkers, including a specific application for COVID-19.

How does AditxtScore for COVID-19 work?

AditxtScore for COVID-19 detects antibodies against SARS-CoV-2, providing insights into immune response to the virus.

What potential does the AditxtScore Center have for Aditxt, Inc.?

The center is critical for commercializing the AditxtScore platform and expanding into markets with significant growth opportunities.

Is AditxtScore approved by the FDA?

AditxtScore is a CLIA-validated laboratory developed test (LDT) but is not FDA-cleared or approved.